Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Wang, Eunice S; Issa, Ghayas C; Erba, Harry P; Altman, Jessica K; Montesinos, Pau; DeBotton, Stephane; Walter, Roland B; Pettit, Kristen; Savona, Michael R; Shah, Mithun Vinod; Kremyanskaya, Marina; Baer, Maria R; Foran, James M; Schiller, Gary; Adès, Lionel; Heiblig, Mael; Berthon, Celine; Peterlin, Pierre; Rodríguez-Arbolí, Eduardo; Salamero, Olga; Patnaik, Mrinal M; Papayannidis, Cristina; Grembecka, Jolanta; Cierpicki, Tomasz; Clegg, Bradley; Ray, Joshua; Linhares, Brian M; Nie, Kun; Mitra, Amitava; Ahsan, Julie Mackey; Tabachri, Marilyn; Soifer, Harris S; Corum, Daniel; Leoni, Mollie; Dale, Stephen; Fathi, Amir T

doi:10.1016/s1470-2045(24)00386-3

The Lancet Oncology

2024

DOI: 10.1016/s1470-2045(24)00386-3

|View full text |Cite|

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Eunice S Wang,

Ghayas C Issa,

Harry P Erba

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Jamil,

Qureshi,

El-amir

et al. 2025

Leukemia Research Reports

View full text Add to dashboard Cite

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Jamil,

Qureshi,

El-amir

et al. 2025

Leukemia Research Reports

View full text Add to dashboard Cite

Functions of the native NPM1 protein and its leukemic mutant

Falini,

Sorcini,

Perriello

et al. 2024

Leukemia

View full text Add to dashboard Cite

Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions

Dhiman,

Dhillon,

Balasubramanian

2024

Cancers

View full text Add to dashboard Cite

Germline mutations in the MEN1 gene encoding menin protein cause multiple endocrine neoplasia type 1 (MEN1) syndrome. Recent evidence suggests that inhibiting the interaction of menin with its crucial oncogenic protein partners represents a promising therapeutic strategy to AML. Menin plays a critical role in lysine methyltransferase 2A (KMT2A)-gene-rearranged and NPM1-m acute leukemias, both associated with adverse outcomes with current standard therapies, especially in the relapsed/refractory setting. Disrupting the menin–KMT2A interaction affects the proleukemogenic HOX/MEIS transcription program. This disruption leads to the differentiation of KMT2Ar and NPM1-m AML cells. Small molecular inhibitors of the menin–KMT2A interaction target the central cavity of MEN1 to inhibit the MEN1-KMT2A interaction and could target a similar transcriptional dependency in other leukemia subsets, broadening their therapeutic potential. These agents, both as monotherapies and in combination with synergistic drugs, are undergoing preclinical and clinical evaluation with promising early results. With the growing literature around menin inhibitors in AML, we discussed the biology of menin, its mechanism of action, its interacting partners in leukemia, possible inhibitors, their implications, synergistic drugs, and future therapeutic strategies in this review.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial

Cited by 4 publications

References 26 publications

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Targeting menin for precision therapy in high-risk acute myeloid leukemia

Functions of the native NPM1 protein and its leukemic mutant

Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions

Contact Info

Product

Resources

About